[2022 ESMO] 에이비온 발표 포스터 3

작성일

2023-08-23 13:59

A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

« [2022 ESMO] 에이비온 발표 포스터 2

[2022 ASCO] 에이비온 발표 포스터 »

목록보기